Key points from article :
The Wyss Center has announced the CE (Conformité Européenne) mark Class I medical device for its NeuroKey BCI.
First clinical application to be launched in the European Union (EU) and work directly with implantable devices.
A CE mark demonstrates that a product deemed to meet EU safety, health and environmental protection requirements.
It is currently in home-use as part of a single case study for a user who is locked-in because of ALS.
Decodes intention from neural signals acquired from implanted electrodes in real-time.
An auditory feedback speller prompts the user to select letters to form words and sentences.
Provides a Yes/No question option to enable quick responses.
Simple user-friendly graphical interface makes it easy to launch and calibrate the BCI system.
Integrating with ABILITY to restore movement and communication.
Integration with monitoring devices to process physiological data.
Could speed up diagnosis of neurological disorders, improve treatments and store memories artificially.
simple home use of BCI is now closer to reality with the new Wyss center's
